Rifapentine plus isoniazid for latent tuberculosis infection in Brazil: a retrospective cohort study

被引：0
|
作者：
Chaves, Beatriz [1 ]
Souza, Ana Carolina [1 ]
Leung, Janaina [1 ]
Costa, Walter [1 ]
Santos, Ana Paula [1 ]
机构：
[1] Univ Estado Rio De Janeiro, Rio De Janeiro, Brazil
来源：
EUROPEAN RESPIRATORY JOURNAL | 2024年 / 64卷
关键词：
D O I：
10.1183/13993003.congress-2024.PA1468
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study
    Radtke, Kendra K.
    Ernest, Jacqueline P.
    Zhang, Nan
    Ammerman, Nicole C.
    Nuermberger, Eric
    Belknap, Robert
    Boyd, Rosanna
    Sterling, Timothy R.
    Savic, Rada M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (12)
  • [22] Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice
    Froberg, Gabrielle
    Jansson, Lena
    Bruchfeld, Judith
    EUROPEAN RESPIRATORY JOURNAL, 2019, 53 (02)
  • [23] Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study
    Denholm, Justin T.
    McBryde, Emma S.
    Eisen, Damon P.
    Penington, Jocelyn S.
    Chen, Caroline
    Street, Alan C.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2014, 6 : 145 - 149
  • [24] Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events
    Lin, Shang-Yi
    Chiu, Yi-Wen
    Lu, Po-Liang
    Hwang, Shang-Jyh
    Chen, Tun-Chieh
    Hsieh, Min-Han
    Chen, Yen-Hsu
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2019, 52 (01) : 158 - 162
  • [25] Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study
    Malik, Amyn A.
    Farooq, Saira
    Jaswal, Maria
    Khan, Hiba
    Nasir, Kumail
    Fareed, Usama
    Shahbaz, Shumail
    Amanullah, Farhana
    Safdar, Nauman
    Khan, Aamir J.
    Keshavjee, Salmaan
    Becerra, Mercedes C.
    Hussain, Hamidah
    LANCET CHILD & ADOLESCENT HEALTH, 2021, 5 (05): : 350 - 356
  • [26] Three Months of Weekly Rifapentine Plus Isoniazid for Latent Tuberculosis Treatment in Solid Organ Transplant Candidates.
    Knoll, B.
    Nog, R.
    Wu, Y.
    Dhand, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 730 - 730
  • [27] Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates
    Simkins, Jacques
    Abbo, Lilian Margarita
    Camargo, Jose Fernando
    Rosa, Rossana
    Morris, Michele Ileana
    TRANSPLANTATION, 2017, 101 (06) : 1468 - 1472
  • [28] Determinants of losses in the latent tuberculosis cascade of care in Brazil: A retrospective cohort study
    Araujo, Nelia C. N.
    Cruz, Constanca M. S.
    Arriaga, Maria B.
    Cubillos-Angulo, Juan M.
    Rocha, Michael S.
    Silveira-Mattos, Paulo S.
    Matos, Gisela M.
    Marques, Izabella M. B.
    Espirito Santo, Isa Carolina P.
    Matos, Gisela M.
    Marques, Izabella M. B.
    Espirito Santo, Isa Carolina P.
    Almeida, Luiza L.
    Andrade, Caroline M.
    Souza, Leonardo A.
    Netto, Eduardo M.
    Andrade, Bruno B.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 93 : 277 - 283
  • [29] Iadhere Study: Cost-Effectiveness Of Self-Administered Isoniazid/rifapentine For Treatment Of Latent Tuberculosis Infection In The United States
    Holland, D. P.
    Sheehan, D.
    Wright, A.
    Scott, N. A.
    Belknap, R. W.
    Borisov, A. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [30] Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis
    Tseng, Shao-Yu
    Huang, Yi-Shin
    Chang, Tien-En
    Perng, Chin-Lin
    Huang, Yi-Hsiang
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2021, 84 (11) : 993 - 1000
12345